Cargando…
EZH2 mediates lidamycin-induced cellular senescence through regulating p21 expression in human colon cancer cells
Lidamycin (LDM) is a novel member of the enediyne antibiotics identified in China with potent antitumor activity. However, it remains unclear whether LDM has potential molecular targets that may affect its antitumor activity. Enhancer of zeste homolog 2 (EZH2) functions as a histone lysine methyltra...
Autores principales: | Sha, Ming-Quan, Zhao, Xiao-Li, Li, Liang, Li, Li-Hui, Li, Yi, Dong, Tian-Geng, Niu, Wei-Xin, Jia, Li-Jun, Shao, Rong-Guang, Zhen, Yong-Su, Wang, Zhen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5260875/ https://www.ncbi.nlm.nih.gov/pubmed/27882937 http://dx.doi.org/10.1038/cddis.2016.383 |
Ejemplares similares
-
Site-specific PEGylation of lidamycin and its antitumor activity
por: Li, Liang, et al.
Publicado: (2015) -
Tissue factor-targeted lidamycin inhibits growth and metastasis of colon carcinoma
por: ZHANG, QING, et al.
Publicado: (2013) -
Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis
por: Jiang, Wen-guo, et al.
Publicado: (2013) -
Small antibody fusion proteins with complementarity-determining regions and lidamycin for tumor targeting therapy
por: ZHONG, GEN-SHEN, et al.
Publicado: (2013) -
Transarterial oily chemoembolization with lidamycin shows potent therapeutic efficacy in VX2 rabbit liver tumor
por: Zhong, Genshen, et al.
Publicado: (2015)